News | Breast Imaging | September 26, 2022

QTscan delivers safe, accurate monitoring of breast cancer treatment 

 

QTscan delivers safe, accurate monitoring of breast cancer treatment

September 26, 2022 — The U.S. Food and Drug Administration (FDA) has granted QT Imaging, Inc. 510(K) clearance to calculate the fibroglandular volume (FGV) of the breast and the ratio of FGV to total breast volume (TGV). This ratio can contribute to an assessment of risk for breast cancer and changes in this ratio can be used to measure the efficacy of medication used to treat or prevent breast cancer. 

Unlike traditional breast imaging modalities, the company's QTscan does not require radiation, injection, or compression, and is highly accurate (+ 0.2%), allowing earlier and more frequent monitoring for women undergoing non-surgical breast cancer treatments such as adjuvant chemotherapy, radiation therapy, cryotherapy, and hormone or selective hormone receptor modulation treatments. No other ultrasound-based breast imaging modality is cleared by the FDA to quantify fibroglandular volume. 

"The ability to determine a therapeutic clinical response using a quantitative volumetric method is crucial for effective and timely treatment of breast cancer and for patients at high risk for developing breast cancer who are receiving hormonal therapy. The FGV tool will allow this assessment to be made early and in follow-up to maximize treatment benefit, which is an exciting development for breast care patients," said Dr. Elaine Iuanow, a Breast Imaging specialist and medical consultant for QT Imaging. 

"We are excited to expand the tools available using low frequency transmitted ultrasound volography to serve women, especially those with dense breasts, providing an imaging option that is safe, comfortable, and effective," said Dr. John Klock, CEO, Chief Medical Officer and Founder of QT Imaging, Inc. 

The proposed indications for use, as designated by the FDA as breakthrough, are: 

"The QT Scanner 2000 Model A is for use as an ultrasonic imaging system to provide reflection-mode and transmission-mode images of a patient's breast. The QT Scanner 2000 Model A software also calculates the breast fibroglandular tissue volume (FGV) value and the ratio of FGV to total breast volume (TBV) value as determined from reflection-mode and transmission-mode ultrasound images of a patient's breast. The device is not intended to be used as a replacement for screening mammography." FDA K220933 

For more information visit www.qtimaging.com 

Related Breast Density Content: 

Technologies to Watch in Breast Imaging 

Researchers Publish Exhaustive Review of Breast Density Assessment 

VIDEO: Women Benefit From Mammography Screening Beyond Age 75 

VIDEO: How Contrast-Enhanced Mammography Will Impact Breast Imaging 


Related Content

News | Artificial Intelligence

November 28, 2022 — Flywheel, a leading data management platform for biomedical research and collaboration, is creating ...

Time November 28, 2022
arrow
News | Breast Imaging

November 25, 2022 — Hologic, Inc. will exhibit its extensive portfolio of breast and skeletal health products at the ...

Time November 25, 2022
arrow
News | Artificial Intelligence

November 25, 2022 — Delphinus Medical Technologies has announced the installation of its SoftVue 3D Whole Breast ...

Time November 25, 2022
arrow
News | Ultrasound Women's Health

November 22, 2022 — Sirona Medical, the leader in cloud-native radiology workflow software, today announced a ...

Time November 22, 2022
arrow
News | Ultrasound Women's Health

November 22, 2022 — Delphinus Medical Technologies today announced that it will host demonstrations of the commercially ...

Time November 22, 2022
arrow
Videos | ASTRO

Dr. Frank A. Vicini, MD, FACR, FASTRO, FABS, who is a radiation oncologist with GenesisCare, discussed his findings from ...

Time November 09, 2022
arrow
Feature | Breast Imaging | By Andrew Smith and Paola Wisner

Patients are the motivational driver for innovation in breast imaging companies. Their needs and experiences help ...

Time November 04, 2022
arrow
News | Mammography

November 3, 2022 — Hologic, Inc., a global leader in women’s health, announced that its 3Dimensions mammography system ...

Time November 03, 2022
arrow
News | Breast Density

November 1, 2022 — Onsite Women’s Health, a leading national provider of breast health services, announces with ...

Time November 01, 2022
arrow
News | Breast Imaging

October 31, 2022 — The Breast Cancer Research Foundation (BCRF) has renewed its funding to Elisa Port, MD, and Hanna ...

Time October 31, 2022
arrow
Subscribe Now